journal article·2021-12-24Open access

A Simulation Analysis of an Influenza Vaccine Production Plant in Areas of High Humanitarian Flow. A Preliminary Study for the Region of Norte de Santander (Colombia)

Jefferson E. Contreras-Ropero, Silvia L. Ruiz-Roa, Janet B. García-Martínez, Néstor A. Urbina-Suarez, Germán L. López-Barrera, Andrés F. Barajas-Solano, Antonio Zuorro

Applied Sciences· Volume 12· Issue 1

Abstract

The production of vaccines of biological origin presents a tremendous challenge for researchers. In this context, animal cell cultures are an excellent alternative for the isolation and production of biologicals against several viruses, since they have an affinity with viruses and a great capacity for their replicability. Different variables have been studied to know the system’s ideal parameters, allowing it to obtain profitable and competitive products. Consequently, this work focuses its efforts on evaluating an alternative for producing an anti-influenza biological from MDCK cells using SuperPro Designer v8.0 software. The process uses the DMEN culture medium supplemented with nutrients as raw material for cell development; the MDCK cells were obtained from a potential scale-up with a final working volume of 500 L, four days of residence time, inoculum volume of 10%, and continuous working mode with up to a total of 7400 h/Yr of work. The scheme has the necessary equipment for the vaccine’s production, infection, and manufacture with yields of up to 416,698 units/h. In addition, it was estimated to be economically viable to produce recombinant vaccines with competitive prices of up to 0.31 USD/unit.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Viral Infectious Diseases and Gene Expression in Insects · Transgenic Plants and Applications · Animal Disease Management and Epidemiology

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Environmental Sciences, Universidad Francisco de Paula Santander, Av. Gran Colombia, No. 12E-96, Cucuta 540003, Colombia

Department of Clinical Care and Rehabilitation, Universidad Francisco de Paula Santander, Av. Gran Colombia No. 12E-96, Cucuta 540003, Colombia

Department of Chemical Engineering, Materials and Environment, Sapienza University, Via Eudossiana 18, 00184 Roma, Italy

Funding

Colombian Ministry of Science Technology and Innovation MINCIENCIAS

References (41)

Show source-provided references
1. Reed, C., Chaves, S.S., Kirley, P.D., Emerson, R., Aragon, D., Hancock, E.B., Butler, L., Baumbach, J., Hollick, G., and Bennett, N.M. (2015). Estimating Influenza Disease Burden from Population-Based Surveillance Data in the United States. PLoS ONE, 10.10.1371/journal.pone.0118369 ↗
2. Instituto Nacional de Salud (2021, September 11). Acute Respiratory Infection Event Report, Colombia, 2019, Available online: https://www.ins.gov.co/buscador-eventos/Informesdeevento/INFECCIÓN%20RESPIRATORIA%20AGUDA_2019.pdf.
3. International Organization for Migration (2021, December 10). DTM Survey—Vocation of Venezuelan Population to Stay in Colombia, Colombia, 2020. Available online: https://colombia.iom.int/sites/colombia/files/EYE/Vocacion/INFORME%20DTM%20VILLA%20DEL%20ROSARIO.pdf.
4. Ministerio de Salud y Protección Social de Colombia (2021, September 11). Ten-Year Public Health Plan 2012–2021 of Colombia, Available online: https://www3.paho.org/hq/index.php?option=com_content&view=article&id=8777:2013-plan-decenal-salud-publica-2012-2021-colombia&Itemid=40264&lang=es.
5. Ministerio de Salud y Protección Social de Colombia (2021, September 11). ABC of the Ten-Year Public Health Plan, Available online: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/PSP/IMP_4feb+ABCminsalud.pdf.
6. Instituto Departamental de Salud de Norte de Santander (2021, December 10). Health Situation Analysis with the Social Determinants Model Norte de Santander Department 2019, Colombia, Available online: https://ids.gov.co/web/2020/TRANSPARENCIA/ASIS_DPTAL_NTE%20SDER_2019_ABRIL_2020.pdf.
7. Modelling and Optimization of Eurycoma longifolia Water Extract Production10.1205/fbp.06004 ↗
8. Global production capacity of seasonal and pandemic influenza vaccines in 201910.1016/j.vaccine.2020.12.018 ↗
9. Polio endgame: Lessons for the global rotavirus vaccination program10.1016/j.vaccine.2019.04.023 ↗
10. Canizales, L., Rojas, F., Pizarro, C.A., Caicedo-Ortega, N.H., and Villegas-Torres, M.F. (2020). SuperPro Designer®, User-Oriented Software Used for Analyzing the Techno-Economic Feasibility of Electrical Energy Generation from Sugarcane Vinasse in Colombia. Processes, 8.10.3390/pr8091180 ↗
11. Process simulation for recombinant protein production: Cost estimation and sensitivity analysis for heparinase I expressed in Escherichia coli10.1002/(SICI)1097-0290(19970320)53:6<575::AID-BIT5>3.0.CO;2-J ↗
12. Rational design of medium supplementation strategy for improved influenza viruses production based on analyzing nutritional requirements of MDCK Cells10.1016/j.vaccine.2014.10.067 ↗
13. Designing cell lines for viral vaccine production: Where do we stand?10.1002/biot.201400388 ↗
14. Differential susceptibility of different cell lines to swine-origin influenza A H1N1, seasonal human influenza A H1N1, and avian influenza A H5N1 viruses10.1016/j.jcv.2009.09.013 ↗
15. A simplified roller bottle platform for the production of a new generation VLPs rabies vaccine for veterinary applications10.1016/j.cimid.2019.04.009 ↗
16. Risks linked to endogenous retroviruses for vaccine production: A general overview10.1016/j.biologicals.2010.01.006 ↗
17. Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process10.1002/bit.22753 ↗
18. Simulation for the recovery of plasmid for a DNA vaccine10.1016/j.bej.2013.09.006 ↗
19. Petrides, D., Carmichael, D., Siletti, C., and Koulouris, A. (2014). Biopharmaceutical Process Optimization with Simulation and Scheduling Tools. Bioengineering, 1.10.3390/bioengineering1040154 ↗
20. Cloning and assessment of tumorigenicity and oncogenicity of a Madin–Darby canine kidney (MDCK) cell line for influenza vaccine production10.1016/j.vaccine.2009.11.023 ↗
21. Power Law Distribution: Method of Multi-Scale Inferential Statistics
22. Comparative study of influenza virus replication in Vero and MDCK cell lines10.1016/j.jviromet.2004.03.011 ↗
23. Valero, Y., Olveira, J., López-Vázquez, C., Dopazo, C., and Bandín, I. (2021). BEI Inactivated Vaccine Induces Innate and Adaptive Responses and Elicits Partial Protection upon Reassortant Betanodavirus Infection in Senegalese Sole. Vaccines, 9.10.3390/vaccines9050458 ↗
24. Progress in Vaccine Development10.1002/9780471729259.mc1801s36 ↗
25. Clinical Efficacy of Cell Culture–Derived and Egg-Derived Inactivated Subunit Influenza Vaccines in Healthy Adults10.1086/656578 ↗
26. Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study10.1080/21645515.2016.1182270 ↗
27. Non-inferiority of mammalian cell-derived quadrivalent subunit influenza virus vaccines compared to trivalent subunit influenza virus vaccines in healthy children: A phase III randomized, multicenter, double-blind clinical trial10.1016/j.ijid.2015.11.004 ↗
28. A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine10.1016/j.vaccine.2009.07.083 ↗
29. Safety and Immunogenicity of a Novel Influenza Subunit Vaccine Produced in Mammalian Cell Culture10.1086/605505 ↗
30. Ministerio de Salud y Protección Social de Colombia (2021, December 10). Guidelines for the Management and Administration of the Expanded Program on Immunization—API—2020, Colombia, 2020, Available online: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/ET/lineamientos-nacionales-pai2020.pdf.
31. Comparative Study between Avian Cell and Mammalian Cell in Production of Influenza Vaccine Shariah Compliance10.1088/1757-899X/778/1/012029 ↗
32. Process economics of industrial monoclonal antibody manufacture10.1016/j.jchromb.2006.07.037 ↗
33. Improved virus purification processes for vaccines and gene therapy10.1002/bit.25545 ↗
34. Perfusion Seed Cultures Improve Bio-pharmaceutical Fed-Batch Production Capacity and Product Quality10.1002/btpr.1884 ↗
35. Bioreactors for high cell density and continuous multi-stage cultivations: Options for process intensification in cell culture-based viral vaccine production10.1007/s00253-015-7267-9 ↗
36. Biomanufacturing evolution from conventional to intensified processes for productivity improvement: A case study10.1080/19420862.2020.1770669 ↗
37. Cell culture-derived flu vaccine: Present and future10.1080/21645515.2018.1460297 ↗
38. Landscaping the structures of GAVI country vaccine supply chains and testing the effects of radical redesign10.1016/j.vaccine.2015.07.033 ↗
39. A planning model for the WHO-EPI vaccine distribution network in developing countries10.1080/0740817X.2013.813094 ↗
40. Haidari, L.A., Connor, D.L., Wateska, A.R., Brown, S.T., Mueller, L.E., Norman, B.A., Schmitz, M.M., Paul, P., Rajgopal, J., and Welling, J.S. (2013). Augmenting Transport versus Increasing Cold Storage to Improve Vaccine Supply Chains. PLoS ONE, 8.10.1371/annotation/b428dad2-e829-4289-acae-c44369d55a80 ↗
41. A review of integrated supply chain network design models: Key issues for vaccine supply chains10.1016/j.cherd.2016.02.015 ↗